Jeremy M. Levin, D.Phil., MB BChir, has been our chief executive officer since March 2015 and chairman of our board of directors since April 2014. Prior to joining us, Dr. Levin was president and chief executive officer of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), the world’s largest generics drug company.  Previously, he was a member of the Executive Committee of Bristol-Myers Squibb (NYSE: BMY) where he had global responsibilities for strategy, alliances and transactions. In this role, he devised and led the BMS “String of Pearls” strategy, which resulted in the transformation of the company. Prior to BMS, Dr. Levin served as global head of strategic alliances at Novartis Institutes for Biomedical Research, Inc. (NYSE:NVS). Dr. Levin has served on a number of public and private company board of directors, and currently serves on the Board of Directors of BIO and Lundbeck (OMX: LUN). Dr. Levin is the chairman of the Biotechnology Innovation Organization (BIO). He is the recipient of numerous awards and was voted as one of the 25 most influential biotechnology leaders by Fierce Biotech. He is the recipient of numerous awards and was voted as one of the 25 most influential biotechnology leaders by Fierce Biotech in 2014. He has practiced medicine as a physician at university hospitals in England, South Africa and Switzerland. Dr. Levin earned his B.A. in zoology, M.A. in cell biology and DPhil. in chromatin structure, all from University of Oxford, and his MB and BChir from the University of Cambridge.